Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | EEF2K | O00418 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CPA3 | P15088 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19817286 | 1.00 | GABBR2 (0.48) | GABBR2GABBR1CYP2C19MAPTEEF2K | |
| SCHEMBL7400131 | 0.88 | PREP (0.43) | GABBR2GABBR1PREPTACR1PDPK1 | |
| SCHEMBL21273146 | 0.85 | FFAR1 (0.46) | CYP2C19FNTAFNTBFFAR1CYP2D6 | |
| SCHEMBL21272987 | 0.85 | FFAR1 (0.46) | CYP2C19FNTAFNTBFFAR1CYP2D6 | |
| SCHEMBL9360109 | 0.85 | ESR1 (0.58) | FFAR1SRC | |
| SCHEMBL4778263 | 0.85 | CYP2C19 (0.47) | GABBR2GABBR1CYP2C19PREPTACR1 | |
| SCHEMBL28555786 | 0.85 | PREP (0.44) | GABBR2GABBR1CYP2C19MAPTPREP | |
| Hydrochloric Acid SCHEMBL6557844 | 0.83 | CYP2C19 (0.46) | GABBR2GABBR1CYP2C19PREPTACR1 | |
| SCHEMBL3660011 | 0.83 | KYNU (0.44) | GABBR2GABBR1FFAR1 | |
| SCHEMBL3658761 | 0.83 | KYNU (0.44) | GABBR2GABBR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217403-A | Cinacalcet hydrochloride synthesis method | 山东能源集团新材料有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-109456201-B | Method for asymmetrically synthesizing (R) -cinacalcet | 中国农业大学 | 2020-04-28 | — | — | CN | claimed |
| CN-103739500-B | A kind of synthesis of cinacalcet hydrochloride and process for purification | SINOPHARM YIXIN PHARMACEUTICAL CO., LTD. (CN) | 2016-03-23 | — | — | CN | claimed |
| CN-103739500-A | Method for synthesizing and refining cinacalcet hydrochlorid | SINOPHARM HOLDING YIXIN PHARMACEUTICAL CO LTD | 2014-04-23 | — | — | CN | claimed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| CN-119486565-A | Perovskite precursor solution, perovskite solar cell, preparation method and photovoltaic module | 天合光能股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4263502-B1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-20240083845-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-03-14 | — | — | US | disclosed |
| EP-4263502-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023139241-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2023-07-27 | — | — | WO | disclosed |
| CN-116217403-A | Cinacalcet hydrochloride synthesis method | 山东能源集团新材料有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20090023801-A1 | INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-0541407-B1 | Nitrogen containing bicyclic derivatives, method for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1997-02-26 | — | — | EP | disclosed |
| US-5384322-A | Prolylendopeptidase inhibitors; Alzheimer*s disease; antidepressant and anxiolytic agents | ADIR ET COMPAGNIE (FR) | 1995-01-24 | — | — | US | disclosed |
| US-5286732-A | Prolylendopeptidase-inhibitors; administering for treatment and prevention of memory disorders for aging | ADIR ET COMPAGNIE (FR) | 1994-02-15 | — | — | US | disclosed |
| EP-0541407-A1 | Nitrogen containing bicyclic derivatives, method for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-05-12 | — | — | EP | disclosed |
| EP-0528172-A1 | (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | GABBR2 2603/4885GABBR1 3078/4885CYP2C19 162/4885 |
| US-20090023801-A1 | INHIBITORS OF BETA AMYLOID PRODUCTION | GYS1, APP, PSEN1 | GABBR2 4137/4885GABBR1 4243/4885CYP2C19 1663/4885 |
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, SENP7 | GABBR2 2552/4885GABBR1 2723/4885CYP2C19 1369/4885 |
| US-20240083845-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | ACE2, SARS1, ACE | GABBR2 2921/4885GABBR1 4047/4885CYP2C19 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.